Aratana Therapeutics (Aratana Therapeutics) Marketable Securities : $0.50 Mil (As of Mar. 2019)

View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Aratana Therapeutics's Marketable Securities for the quarter that ended in Mar. 2019 was $0.50 Mil.

Aratana Therapeutics's annual Marketable Securities declined from Dec. 2016 ($1.00 Mil) to Dec. 2017 ($0.75 Mil) but then increased from Dec. 2017 ($0.75 Mil) to Dec. 2018 ($1.24 Mil).

Aratana Therapeutics Marketable Securities Historical Data

The historical data trend for Aratana Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aratana Therapeutics Marketable Securities Chart

Aratana Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Marketable Securities

Get a 7-Day Free Trial

88.25

59.45

1.00

0.75

1.24

Aratana Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Marketable Securities	Get a 7-Day Free Trial															0.50	0.74	1.74	1.24	0.50

Aratana Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Aratana Therapeutics (NAS:PETX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Aratana Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aratana Therapeutics (Aratana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211

Website

http://www.aratana.com

Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.

Executives

Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Vort John Vander	director	C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson	director	470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno	director
David L Brinkley	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh	director	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr	director	SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman	director, officer: President and CEO
Peter Steven St	director, officer: PRESIDENT AND CEO	MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211